LungLife AI

LungLife AI is a developer of clinical diagnostic solutions focused on the early detection of lung cancer, the deadliest cancer globally. The company's flagship product, LungLB®, is a minimally invasive blood-based test designed to provide clinicians with additional information to help them make informed decisions about the management of lung nodules and lung cancer. This simple blood test aims to improve patient outcomes by identifying cancer at an earlier stage when treatment options are more effective.

LungLife AI is committed to working collaboratively with scientific and clinical partners to achieve its purpose of being a driving force in the early detection of lung cancer. The company is actively seeking opportunities for a strategic partner to accelerate the adoption of LungLB® and make it more accessible to patients who need it most. LungLife AI is dedicated to inverting the 20:80 ratio of late-stage lung cancer detection, aiming for a future where at least 80% of lung cancer is diagnosed early.

LungLife AI is a developer of clinical diagnostic solutions dedicated to revolutionizing the early detection of lung cancer, the deadliest cancer globally. Their mission is to invert the 20:80 ratio of late-stage to early-stage lung cancer diagnoses, ensuring that at least 80% of lung cancers are detected early. To achieve this, LungLife AI has developed the LungLB® test, a minimally invasive blood draw that provides clinicians with additional information to make informed decisions about the management of lung nodules and lung cancer.

LungLife AI prioritizes collaboration and transparency in its company culture. They are dedicated to working with scientific and clinical partners to advance the early detection of lung cancer. This collaborative spirit extends internally, with a supportive environment where honesty and transparency are valued.